Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities

Autor: Canhua Xiao, PhD, Jennifer Moughan, MS, Benjamin Movsas, MD, Andre A. Konski, MD, Gerald E. Hanks, MD, James D. Cox, MD, Mack Roach, III, MD, Kenneth L. Zeitzer, MD, Colleen A. Lawton, MD, Christopher A. Peters, MD, Seth A. Rosenthal, MD, I.-Chow Joe Hsu, MD, Eric M. Horwitz, MD, Mark V. Mishra, MD, Jeff M. Michalski, MD, Matthew B. Parliament, MD, David P. D'Souza, MD, Stephanie L. Pugh, PhD, Deborah W. Bruner, PhD

Publikováno v: Advances in Radiation Oncology, Vol 3, Iss 3, Pp 405-411 (2018)

Purpose: A meta-analysis of sociodemographic variables and their association with late (>180 days from start of radiation therapy[RT]) bowel, bladder, and clustered bowel and bladder toxicities was conducted in patients with high-risk (clinical stage

Externí odkaz: https://doaj.org/article/6ff723a9aa3647fc883ffb1eee1dce8a

Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities

Autor: Kenneth L. Zeitzer, Colleen A. Lawton, Gerald E. Hanks, Canhua Xiao, Matthew Parliament, Jeff M. Michalski, Seth A. Rosenthal, David D'Souza, Deborah Watkins Bruner, I. Chow Joe Hsu, Mack Roach, Mark V. Mishra, Stephanie L. Pugh, Benjamin Movsas, Jennifer Moughan, Eric M. Horwitz, James D. Cox, Christopher A. Peters, Andre Konski

Publikováno v: Advances in radiation oncology, vol 3, iss 3
Advances in Radiation Oncology, Vol 3, Iss 3, Pp 405-411 (2018)
Advances in Radiation Oncology

Purpose: A meta-analysis of sociodemographic variables and their association with late (>180 days from start of radiation therapy[RT]) bowel, bladder, and clustered bowel and bladder toxicities was conducted in patients with high-risk (clinical stage

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e797fa72b634f95a499e7cf6f80bb809
https://escholarship.org/uc/item/1qg1f07c

Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202

Autor: Meena Bedi, Howard M. Sandler, James J. Dignam, Seth A. Rosenthal, Colleen A. Lawton, Harold Kim, Xiaolei Lin, Harmar D. Brereton, Young Kwok, Rachel Rabinovitch, Eric M. Horwitz, Matthew Parliament, Varagur Venkatesan, Thomas M. Pisansky, David J. Grignon, Kenneth L. Zeitzer, Gerald E. Hanks, Herbert Lepor, Mack Roach

Publikováno v: Lawton, CAF; Lin, X; Hanks, GE; Lepor, H; Grignon, DJ; Brereton, HD; et al.(2017). Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. International Journal of Radiation Oncology Biology Physics, 98(2), 296-303. doi: 10.1016/j.ijrobp.2017.02.004. UCSF: Retrieved from: http://www.escholarship.org/uc/item/2hv212wt

© 2017 Purpose Trial RTOG 9202 was a phase 3 randomized trial designed to determine the optimal duration of androgen deprivation therapy (ADT) when combined with definitive radiation therapy (RT) in the treatment of locally advanced nonmetastatic ad

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdeff8b23ba4677bc1406fa805320d73
http://www.escholarship.org/uc/item/2hv212wt

Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes

Autor: Kiri A. Sandler, Matthew Rettig, Robert E. Reiter, Nicholas G. Nickols, Theo M. de Reijke, Alexandra Drakaki, W. Seiferheld, Xiaoyan Wang, Christopher R. King, Michel Bolla, Michael L. Steinberg, Howard M. Sandler, Gerald E. Hanks, Philippe Maingon, Daniel E. Spratt, Laurence Collette, Amar U. Kishan, Patrick A. Kupelian

Publikováno v: JAMA oncology, 5(1), 91-96. American Medical Association

IMPORTANCE: Androgen deprivation therapy (ADT) improves survival outcomes in patients with high-risk prostate cancer (PCa) treated with radiotherapy (RT). Whether this benefit differs between patients with Gleason grade group (GG) 4 (formerly Gleason

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c45280f4cde40d97a2df9bd0782a2207
https://doi.org/10.1001/jamaoncol.2018.3732

MDM2 and Ki-67 Predict for Distant Metastasis and Mortality in Men Treated With Radiotherapy and Androgen Deprivation for Prostate Cancer: RTOG 92-02

Autor: Li Yan Khor, Alan Pollack, Mingxin Che, Marvin Rotman, Roger W. Byhardt, M. Elizabeth H. Hammond, Tahseen Al-Saleem, David J. Grignon, Howard M. Sandler, Varagur Venkatesan, Kyounghwa Bae, Rebecca Paulus, Gerald E. Hanks

Publikováno v: Journal of Clinical Oncology. 27:3177-3184

Purpose MDM2 regulates p53, which controls cell cycle arrest and apoptosis. Both proteins, along with Ki-67, which is an established strong determinant of metastasis, have shown promise in predicting the outcome of men treated with radiation therapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::921e5f68d4e02cd81552f5729c9a9667
https://doi.org/10.1200/jco.2008.19.8267